Related content

Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome

By Wu Jie   Zhu Yiqing   Jiang Yunfei   Cao Yaoping  

Gynecological Endocrinology, Vol. 24, Iss. 7, 2008-01 ,pp. : 392-398

Informa Healthcare

Access to resources Recommend Favorite

Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol–cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study

By Elter Koray   Imir Gonca   Durmusoglu Fatih  

Human Reproduction, Vol. 17, Iss. 7, 2002-07 ,pp. : 1729-1737

Oxford University Press

Access to resources Recommend Favorite

Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: A randomized, double-blind, and placebo control trial

By Fux Otta CarolinaFux   Wior Myriam   Iraci Gabriel S.   Kaplan Raquel   Torres Diana   Gaido María Isabel   Wyse Eduardo P.  

Gynecological Endocrinology, Vol. 26, Iss. 3, 2010-03 ,pp. : 173-178

Informa Healthcare

Access to resources Recommend Favorite

Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects

By Nardo L. G.   Rai R.  

Gynecological Endocrinology, Vol. 15, Iss. 5, 2001-10 ,pp. : 373-380

Informa Healthcare

Access to resources Recommend Favorite

Andrea C. Gore (ed): Endocrine-disrupting Chemicals: From Basic Research to Clinical Practice: Humana Press, NJ, 2007, Hardcover, XII, 361 pp, $139.00

By Cooper Ralph  

Endocrine Journal, Vol. 32, Iss. 3, 2007-12 ,pp. : 354-355

Humana Press, Inc

Access to resources Recommend Favorite